Publicacions en col·laboració amb investigadors/es de Fundación Hospital Alcorcón (28)

2020

  1. Holistic approach of the care of the infant with hypoxic-ischaemic encephalopathy in Spain

    Anales de Pediatria, Vol. 92, Núm. 5, pp. 286-296

2019

  1. Cannabidiol administration prevents hypoxia-ischemia-induced hypomyelination in newborn rats

    Frontiers in Pharmacology, Vol. 10, Núm. SEP

  2. aEEG and neurologic exam findings correlate with hypoxic–ischemic brain damage severity in a piglet survival model

    Pediatric Research, Vol. 85, Núm. 4, pp. 539-545

2017

  1. Neuroprotective effects of cannabidiol in hypoxic ischemic insult. The therapeutic window in newborn mice

    CNS and Neurological Disorders - Drug Targets, Vol. 16, Núm. 1, pp. 102-108

2013

  1. Mechanisms of cannabidiol neuroprotection in hypoxic-ischemic newborn pigs: Role of 5HT1A and CB2 receptors

    Neuropharmacology, Vol. 71, pp. 282-291

2012

  1. β-Amyloid exacerbates inflammation in astrocytes lacking fatty acid amide hydrolase through a mechanism involving PPAR-α, PPAR-γ and TRPV1, but not CB1 or CB2 receptors

    British Journal of Pharmacology, Vol. 166, Núm. 4, pp. 1474-1489

2011

  1. Cannabidiol reduces lipopolysaccharide-induced vascular changes and inflammation in the mouse brain: An intravital microscopy study

    Journal of Neuroinflammation, Vol. 8

  2. The impact of clinical maternal chorioamnionitis on neurological and psychological sequelae in very-low-birth weight infants: A case-control study

    Journal of Perinatal Medicine, Vol. 39, Núm. 2, pp. 203-208

2010

  1. The endocannabinoid system and amyloid-related diseases

    Experimental Neurology, Vol. 224, Núm. 1, pp. 66-73

  2. The neuroprotective effect of cannabidiol in an in vitro model of newborn hypoxic-ischemic brain damage in mice is mediated by CB2 and adenosine receptors

    Neurobiology of Disease, Vol. 37, Núm. 2, pp. 434-440

2009

  1. Cannabinoids and neurodegenerative diseases

    CNS and Neurological Disorders - Drug Targets, Vol. 8, Núm. 6, pp. 440-450

  2. Codificación en neurología pediátrica basada en la Clasificación Internacional de Enfermedades, 9. a revisión (CIE-9), 5. a edición (2006)

    Revista de Neurologia, Vol. 48, Núm. 2, pp. 58-60

  3. The activation of cannabinoid CB2 receptors stimulates in situ and in vitro beta-amyloid removal by human macrophages

    Brain Research, Vol. 1283, pp. 148-154

2008

  1. Neuroprotective effects of the nonpsychoactive cannabinoid cannabidiol in hypoxic-ischemic newborn piglets

    Pediatric Research, Vol. 64, Núm. 6, pp. 653-658

2007

  1. Agenesia traqueal asociada a malformaciones laríngeas como causa inusual de fracaso de la vía aérea

    Anales de Pediatria, Vol. 67, Núm. 3, pp. 236-239

  2. Terapia de grupo para el tratamiento de la obesidad infantil

    Anales de Pediatria, Vol. 67, Núm. 1, pp. 51-56

  3. The cannabinoid agonist WIN55212 reduces brain damage in an in vivo model of hypoxic-ischemic encephalopathy in newborn rats

    Pediatric Research, Vol. 62, Núm. 3, pp. 255-260

  4. The seek of neuroprotection: Introducing cannabinoids

    Recent Patents on CNS Drug Discovery, Vol. 2, Núm. 2, pp. 131-139

2006

  1. Characterization of the neuroprotective effect of the cannabinoid agonist WIN-55212 in an in vitro model of hypoxic-ischemic brain damage in newborn rats

    Pediatric Research, Vol. 60, Núm. 2, pp. 169-173

  2. Nitric oxide synthase as a target for the prevention of hypoxic-ischemic newborn brain damage

    Current Enzyme Inhibition, Vol. 2, Núm. 3, pp. 219-229